Sign in or create an account to add this stock to your watchlist.
About Synergy Pharmaceuticals (NASDAQ:SGYP)
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SGYP
CUSIP87163930
Phone212-297-0020
Debt
Debt-to-Equity Ratio-3.01
Current Ratio3.09
Quick Ratio2.71
Price-To-Earnings
Trailing P/E Ratio-1.60
Forward P/E Ratio-2.76
P/E GrowthN/A
Sales & Book Value
Annual Sales$16.82 million
Price / Sales23.91
Cash FlowN/A
Price / CashN/A
Book Value($0.16) per share
Price / Book-10.19
Profitability
EPS (Most Recent Fiscal Year)($1.02)
Net Income$-224,330,000.00
Net Margins-773.82%
Return on Equity-652.66%
Return on Assets-145.45%
Miscellaneous
Employees313
Outstanding Shares246,740,000
Synergy Pharmaceuticals (NASDAQ:SGYP) Frequently Asked Questions
What is Synergy Pharmaceuticals' stock symbol?
Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."
How were Synergy Pharmaceuticals' earnings last quarter?
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) posted its quarterly earnings data on Thursday, May, 10th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.01. The biopharmaceutical company earned $8.59 million during the quarter, compared to analyst estimates of $11.18 million. Synergy Pharmaceuticals had a negative return on equity of 652.66% and a negative net margin of 773.82%. The company's revenue for the quarter was up 776.5% on a year-over-year basis. During the same period last year, the company earned ($0.30) EPS. View Synergy Pharmaceuticals' Earnings History.
What price target have analysts set for SGYP?
8 brokerages have issued 1-year target prices for Synergy Pharmaceuticals' stock. Their forecasts range from $2.50 to $15.00. On average, they expect Synergy Pharmaceuticals' share price to reach $8.8125 in the next year. View Analyst Ratings for Synergy Pharmaceuticals.
What are Wall Street analysts saying about Synergy Pharmaceuticals stock?
Here are some recent quotes from research analysts about Synergy Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York. " (5/9/2018)
- 2. Cantor Fitzgerald analysts commented, "As we predicted in a report published last week, SGYP disclosed that the cash balance at the end of January exceeded the $128 million level required to access $100 million from the CRG Term Loan Agreement." (2/1/2018)
Are investors shorting Synergy Pharmaceuticals?
Synergy Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totalling 62,620,901 shares, an increase of 0.3% from the April 30th total of 62,433,759 shares. Based on an average trading volume of 4,543,178 shares, the days-to-cover ratio is presently 13.8 days. Currently, 25.4% of the company's shares are short sold.
Who are some of Synergy Pharmaceuticals' key competitors?
Some companies that are related to Synergy Pharmaceuticals include Motif (MTFB), Cambrex (CBM), ARMO BioSciences (ARMO), Zogenix (ZGNX), Innoviva (INVA), Pacira Pharmaceuticals (PCRX), ImmunoGen (IMGN), Endo International (ENDP), PTC Therapeutics (PTCT), Mallinckrodt (MNK), Myovant Sciences (MYOV), Impax Laboratories (IPXL), Biohaven Pharmaceutical (BHVN), Amneal Pharmaceuticals (AMRX) and TherapeuticsMD (TXMD).
Who are Synergy Pharmaceuticals' key executives?
Synergy Pharmaceuticals' management team includes the folowing people:
- Dr. Gary S. Jacob, Exec. Chairman (Age 71)
- Mr. Troy Hamilton Pharm.D., CEO & Director (Age 46)
- Dr. Kunwar Shailubhai, Chief Scientific Officer and Exec. VP (Age 60)
- Dr. Patrick H. Griffin M.D., FACP, Exec. VP & Chief Medical Officer (Age 63)
- Mr. Gary G. Gemignani, Exec. VP & CFO (Age 53)
Has Synergy Pharmaceuticals been receiving favorable news coverage?
Media stories about SGYP stock have trended somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Synergy Pharmaceuticals earned a media sentiment score of 0.13 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 46.77 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are Synergy Pharmaceuticals' major shareholders?
Synergy Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.62%), Hikari Power Ltd (0.81%), JPMorgan Chase & Co. (0.74%), CVI Holdings LLC (0.72%), Schwab Charles Investment Management Inc. (0.50%) and UBS Group AG (0.47%). Company insiders that own Synergy Pharmaceuticals stock include Gary S Jacob, John P Brancaccio and Paulson & Co Inc. View Institutional Ownership Trends for Synergy Pharmaceuticals.
Which major investors are selling Synergy Pharmaceuticals stock?
Which major investors are buying Synergy Pharmaceuticals stock?
SGYP stock was purchased by a variety of institutional investors in the last quarter, including CVI Holdings LLC, Millennium Management LLC, OMERS ADMINISTRATION Corp, Schwab Charles Investment Management Inc., Mackay Shields LLC, Hikari Power Ltd and MetLife Investment Advisors LLC. Company insiders that have bought Synergy Pharmaceuticals stock in the last two years include Gary S Jacob and John P Brancaccio. View Insider Buying and Selling for Synergy Pharmaceuticals.
How do I buy shares of Synergy Pharmaceuticals?
Shares of SGYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Synergy Pharmaceuticals' stock price today?
One share of SGYP stock can currently be purchased for approximately $1.63.
How big of a company is Synergy Pharmaceuticals?
Synergy Pharmaceuticals has a market capitalization of $414.52 million and generates $16.82 million in revenue each year. The biopharmaceutical company earns $-224,330,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Synergy Pharmaceuticals employs 313 workers across the globe.
How can I contact Synergy Pharmaceuticals?
Synergy Pharmaceuticals' mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company can be reached via phone at 212-297-0020 or via email at [email protected]
MarketBeat Community Rating for Synergy Pharmaceuticals (SGYP)
MarketBeat's community ratings are surveys of what our community members think about Synergy Pharmaceuticals and other stocks. Vote "Outperform" if you believe SGYP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGYP will underperform the S&P 500 over the long term. You may vote once every thirty days.
Synergy Pharmaceuticals (NASDAQ:SGYP) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for Synergy Pharmaceuticals in the last 12 months. Their average twelve-month price target is $8.8125, suggesting that the stock has a possible upside of 440.64%. The high price target for SGYP is $15.00 and the low price target for SGYP is $2.50. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.63 | 2.63 | 2.67 | 2.80 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $8.8125 | $8.8125 | $8.9444 | $8.40 |
| Price Target Upside: | 440.64% upside | 361.39% upside | 325.93% upside | 341.18% upside |
Synergy Pharmaceuticals (NASDAQ:SGYP) Consensus Price Target History
Synergy Pharmaceuticals (NASDAQ:SGYP) Analyst Ratings History
Show:
(Data available from 5/27/2016 forward)
Synergy Pharmaceuticals (NASDAQ:SGYP) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Synergy Pharmaceuticals (NASDAQ SGYP) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.80%
Institutional Ownership Percentage: 44.32%
Synergy Pharmaceuticals (NASDAQ SGYP) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/10/2017 | Paulson & Co. Inc. | Major Shareholder | Sell | 8,750,000 | $2.82 | $24,675,000.00 | |  |
| 8/7/2017 | Paulson & Co. Inc. | Major Shareholder | Sell | 26,287 | $3.77 | $99,101.99 | | |
| 5/26/2017 | Gary S Jacob | CEO | Buy | 5,680 | $3.52 | $19,993.60 | 402,679 | |
| 5/26/2017 | John P Brancaccio | Director | Buy | 6,500 | $3.59 | $23,335.00 | 30,444 | |
| 11/4/2016 | Paulson & Co. Inc. | Major Shareholder | Sell | 140,000 | $4.24 | $593,600.00 | | |
| 9/28/2016 | Paulson & Co. Inc. | Major Shareholder | Sell | 54,300 | $5.69 | $308,967.00 | | |
| 9/19/2016 | John P Brancaccio | Director | Sell | 2,518 | $5.76 | $14,503.68 | 21,883 | |
| 9/19/2016 | Paulson & Co. Inc. | Major Shareholder | Sell | 3,473,713 | $5.61 | $19,487,529.93 | | |
| 9/14/2015 | Bernard Denoyer | SVP | Sell | 10,000 | $7.50 | $75,000.00 | | |
| 9/11/2015 | Alan Joslyn | Director | Sell | 13,754 | $7.22 | $99,303.88 | | |
| 6/3/2014 | John P Brancaccio | Director | Buy | 3,500 | $4.12 | $14,420.00 | | |
| 5/27/2014 | Gary S Jacob | CEO | Buy | 4,000 | $4.18 | $16,720.00 | | |
| 5/23/2014 | Bernard Denoyer | SVP | Buy | 2,500 | $3.89 | $9,725.00 | | |
| 5/23/2014 | Kunwar Shailubhai | Insider | Buy | 3,000 | $3.89 | $11,670.00 | | |
| 10/29/2013 | Gabriel Cerrone | Director | Buy | 12,000 | $4.09 | $49,080.00 | | |
| 6/21/2013 | Bernard Denoyer | SVP | Buy | 7,500 | $4.78 | $35,850.00 | | |
| 6/14/2013 | Gabriel Cerrone | Chairman | Buy | 8,000 | $4.42 | $35,360.00 | | |
| 4/24/2013 | Gabriel Cerrone | Chairman | Buy | 5,500 | $4.66 | $25,630.00 | | |
| 2/5/2013 | Gabriel Cerrone | Chairman | Buy | 5,000 | $6.15 | $30,750.00 | | |
| 2/4/2013 | Gabriel Cerrone | Chairman | Buy | 13,090 | $6.04 | $79,063.60 | | |
| 1/30/2013 | Gabriel Cerrone | Chairman | Buy | 26,000 | $5.98 | $155,480.00 | | |
| 11/14/2012 | Gabriel Cerrone | Chairman | Buy | 87,820 | $3.61 | $317,030.20 | | |
(Data available from 1/1/2013 forward)
Synergy Pharmaceuticals (NASDAQ SGYP) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Synergy Pharmaceuticals Sees Exodus In Institutional Ownership As Management Ignores Dilution Fears
seekingalpha.com - May 25 at 9:06 AM |
 | FY2018 EPS Estimates for Synergy Pharmaceuticals Inc Lowered by Analyst (SGYP)
www.americanbankingnews.com - May 24 at 8:23 AM |
 | Biotech CEO Presents: Merck’s $500M Pain, Our Potential Gain
finance.yahoo.com - May 22 at 8:56 AM |
| $11.60 Million in Sales Expected for Synergy Pharmaceuticals Inc (SGYP) This Quarter
www.americanbankingnews.com - May 22 at 2:12 AM |
| Zacks: Brokerages Anticipate Synergy Pharmaceuticals Inc (SGYP) Will Announce Earnings of -$0.16 Per Share
www.americanbankingnews.com - May 20 at 9:28 PM |
| Synergy Pharmaceuticals Investors: Refocus Away From Management
seekingalpha.com - May 18 at 10:29 AM |
| Synergy Pharmaceuticals 'Evaluating All Options': Does That Mean A Formal Strategic Review?
seekingalpha.com - May 17 at 9:21 AM |
| Q2 2018 EPS Estimates for Synergy Pharmaceuticals (SGYP) Lowered by Oppenheimer
www.americanbankingnews.com - May 16 at 7:27 AM |
| Synergy Pharmaceuticals (SGYP) Given a $7.00 Price Target by BTIG Research Analysts
www.americanbankingnews.com - May 15 at 1:07 PM |
| FY2021 EPS Estimates for Synergy Pharmaceuticals Lifted by Analyst (SGYP)
www.americanbankingnews.com - May 15 at 8:35 AM |
| Edited Transcript of SGYP earnings conference call or presentation 10-May-18 8:30pm GMT
finance.yahoo.com - May 14 at 4:43 PM |
| Synergy Pharmaceuticals (SGYP) PT Set at $7.00 by HC Wainwright
www.americanbankingnews.com - May 14 at 12:42 PM |
| Synergy Pharmaceuticals (SGYP) Rating Reiterated by Oppenheimer
www.americanbankingnews.com - May 14 at 12:42 PM |
| Today’s Research Reports on Stocks to Watch: Regeneron Pharmaceuticals and Synergy Pharmaceuticals
finance.yahoo.com - May 14 at 10:40 AM |
| Synergy Pharmaceuticals: The Short Covering Has Begun
seekingalpha.com - May 13 at 9:37 AM |
| Synergy Pharmaceuticals (SGYP) Posts Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - May 11 at 9:39 PM |
| Synergy Pharmaceuticals: Very Soft First Quarter Fuels The Revolt
seekingalpha.com - May 11 at 4:52 PM |
| Head-To-Head Comparison: Synergy Pharmaceuticals (SGYP) & Tocagen (TOCA)
www.americanbankingnews.com - May 11 at 3:06 PM |
 | Benzinga's Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy's Revenue Miss, FDA Warns E-Liquid Makers Again
www.msn.com - May 11 at 10:13 AM |
 | Synergy Pharma: 1Q Earnings Snapshot
www.cnbc.com - May 11 at 10:13 AM |
| Synergy Pharmaceuticals' (SGYP) CEO Troy Hamilton on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 10:13 AM |
| Synergy Pharmaceuticals Reports First Quarter 2018 Financial Results and Business Update
finance.yahoo.com - May 10 at 4:43 PM |
| Synergy Pharmaceuticals: Activist Group Reaches 26.1 Million Shares
seekingalpha.com - May 10 at 9:27 AM |
| Synergy Pharmaceuticals (SGYP) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - May 9 at 6:02 PM |
| Synergy Pharmaceuticals (SGYP) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - May 7 at 10:36 PM |
| HC Wainwright Analysts Give Synergy Pharmaceuticals (SGYP) a $7.00 Price Target
www.americanbankingnews.com - May 7 at 2:56 PM |
| Synergy Pharmaceuticals (SGYP) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 6 at 7:41 PM |
| Synergy Pharmaceuticals: Activist Group Reaches 20.6 Million Shares
seekingalpha.com - May 6 at 4:48 PM |
| Zacks: Brokerages Expect Synergy Pharmaceuticals (SGYP) Will Announce Quarterly Sales of $10.70 Million
www.americanbankingnews.com - May 5 at 3:43 AM |
| Zacks: Brokerages Anticipate Synergy Pharmaceuticals (SGYP) Will Announce Earnings of -$0.16 Per Share
www.americanbankingnews.com - May 3 at 5:56 PM |
| Synergy Pharmaceuticals (SGYP) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - May 3 at 3:32 AM |
| Synergy Pharmaceuticals Is Facing A Shareholder Revolt - Good
seekingalpha.com - May 1 at 9:07 AM |
| Synergy Pharmaceuticals: Q1 Earnings Preview
seekingalpha.com - April 30 at 10:18 AM |
| Synergy Pharmaceuticals Investors Ask Ackman And Icahn To Intervene
seekingalpha.com - April 30 at 10:18 AM |
| Synergy Pharmaceuticals to Report First Quarter 2018 Financial Results and Host Conference Call and Webcast
finance.yahoo.com - April 25 at 9:41 AM |
| Synergy Pharmaceuticals (SGYP) Stock Rating Reaffirmed by BTIG Research
www.americanbankingnews.com - April 20 at 4:17 PM |
| Options Traders Expect Huge Moves in Synergy Pharmaceuticals (SGYP) Stock
finance.yahoo.com - April 18 at 9:35 AM |
| Synergy Pharmaceuticals (SGYP) Expected to Earn Q1 2018 Earnings of ($0.15) Per Share
www.americanbankingnews.com - April 18 at 7:42 AM |
| -$0.16 EPS Expected for Synergy Pharmaceuticals (SGYP) This Quarter
www.americanbankingnews.com - April 16 at 9:21 AM |
| Synergy Pharmaceuticals (SGYP) Given a $13.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - April 15 at 8:37 AM |
| Synergy Pharmaceuticals (SGYP) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 11 at 6:19 PM |
| Synergy Pharmaceuticals (SGYP) Earns Buy Rating from Cantor Fitzgerald
www.americanbankingnews.com - April 11 at 6:13 PM |
| Synergy Pharmaceuticals (SGYP) Given a $9.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - April 11 at 1:27 PM |
| HC Wainwright Analysts Give Synergy Pharmaceuticals (SGYP) a $15.00 Price Target
www.americanbankingnews.com - April 11 at 12:11 AM |
| SGYP DEADLINE TODAY: The Law Offices of Vincent Wong Reminds Investors of Class Actions Involving Synergy Pharmaceuticals Inc. and a Lead Plaintiff Deadline of April 10, 2018
finance.yahoo.com - April 10 at 4:40 PM |
| FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Synergy Pharmaceuticals Inc. (SGYP) & Lead Plaintiff Deadline: April 10, 2018
finance.yahoo.com - April 10 at 4:40 PM |
| Glancy Prongay & Murray LLP Reminds Investors of the April 10, 2018 Deadline in the Class Action Lawsuit Against Synergy Pharmaceuticals Inc. (SGYP)
finance.yahoo.com - April 10 at 4:40 PM |
| DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The Firm
finance.yahoo.com - April 10 at 4:40 PM |
 | Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Synergy Pharmaceuticals ...
www.businesswire.com - April 10 at 9:29 AM |
| EQUITY NOTICE: Rosen Law Firm Reminds Synergy Pharmaceuticals Inc. Investors of Important April 10, 2018 ...
www.businesswire.com - April 10 at 9:29 AM |
Synergy Pharmaceuticals (NASDAQ:SGYP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Synergy Pharmaceuticals (NASDAQ:SGYP) Income Statement, Balance Sheet and Cash Flow Statement
Synergy Pharmaceuticals (NASDAQ SGYP) Stock Chart for Sunday, May, 27, 2018
Loading chart…
